Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1011

1.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
[PubMed - indexed for MEDLINE]
2.
3.

A systematic review of randomized trials in localized prostate cancer.

Alibhai SM, Klotz LH.

Can J Urol. 2004 Feb;11(1):2110-7. Review.

PMID:
15003149
[PubMed - indexed for MEDLINE]
4.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
[PubMed - indexed for MEDLINE]
5.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
[PubMed - indexed for MEDLINE]
6.

Prostate specific antigen only progression of prostate cancer.

Moul JW.

J Urol. 2000 Jun;163(6):1632-42. Review.

PMID:
10799151
[PubMed - indexed for MEDLINE]
7.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
[PubMed - indexed for MEDLINE]
8.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

PMID:
23126653
[PubMed - indexed for MEDLINE]
Free Article
9.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

PMID:
22239226
[PubMed - indexed for MEDLINE]
10.

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K.

Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7. Review.

PMID:
21984740
[PubMed - indexed for MEDLINE]
11.

Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer?

Merrick GS, Butler WM, Lief JH, Dorsey AT.

Tech Urol. 2001 Mar;7(1):12-9. Review.

PMID:
11272667
[PubMed - indexed for MEDLINE]
12.
13.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

PMID:
11098244
[PubMed - indexed for MEDLINE]
Free Article
14.

Prostate cancer.

Small EJ.

Curr Opin Oncol. 1997 May;9(3):277-86. Review.

PMID:
9229151
[PubMed - indexed for MEDLINE]
15.

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review.

Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

Health Technol Assess. 2003;7(33):iii, ix-x, 1-157. Review.

PMID:
14609482
[PubMed - indexed for MEDLINE]
Free Article
16.

Evaluation and management of the man who has failed primary curative therapy for prostate cancer.

Ornstein DK, Oh J, Herschman JD, Andriole GL.

Urol Clin North Am. 1998 Nov;25(4):591-601. Review.

PMID:
10026768
[PubMed - indexed for MEDLINE]
17.

PSA relapse prostate cancer: the importance of tailored therapy.

Aranha O, Vaishampayan U.

Urol Oncol. 2004 Jan-Feb;22(1):62-9. Review.

PMID:
14969807
[PubMed - indexed for MEDLINE]
18.

Controversies in prostate cancer radiotherapy: consensus development.

Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L; Canadian GU Radiation Oncologist Group.

Can J Urol. 2001 Aug;8(4):1314-22. Review.

PMID:
11564274
[PubMed - indexed for MEDLINE]
19.

Prostate cancer: emerging concepts. Part II.

Garnick MB, Fair WR.

Ann Intern Med. 1996 Aug 1;125(3):205-12. Review.

PMID:
8686979
[PubMed - indexed for MEDLINE]
20.

Variables in predicting survival based on treating "PSA-only" relapse.

Moul JW.

Urol Oncol. 2003 Jul-Aug;21(4):292-304. Review.

PMID:
12954500
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk